This study aims to evaluate the efficacy and safety of HRS-9563 in patients with mild to moderate hypertension, and to explore its appropriate dosage.
The subject voluntarily signs the informed consent form.
Male or female, aged ≥ 18 years and ≤ 75 years;
Patients with mild to moderate hypertension;
At the Screening and Baseline periods, the mean sitting office systolic blood pressure is > 130 mmHg, and the 24-hour mean systolic blood pressure assessed by ABPM at Screening is ≥ 130 mmHg and < 160 mmHg.
Secondary hypertension;
Orthostatic hypotension;
Type 1 diabetes or poorly controlled type 2 diabetes;
Occurrence of any cardiovascular or cerebrovascular event within 6 months prior to screening;